Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2021 | Prognostic impact of bone metastasis in UC

Srikala Sridhar • 15 Feb 2021
GU Cancers 2021
Bladder Cancer Genitourinary Cancer Urothelial Carcinoma

Srikala Sridhar, MD, FRCPC, Princess Margaret Cancer Centre, Toronto, ON, describes a retrospective chart review presented at ASCO GU 2021 of patients with metastatic urothelial carcinoma (mUC) treated with front-line platinum-based chemotherapy from 2005-2018, with the aim of assessing the prognostic impact of bone metastasis on survival outcomes. This study suggested that bone metastasis is a significant predictor of worse outcomes in front-line platinum-based chemotherapy-treated mUC and suggests further study in to bone-targeted agents is necessary. This interview took place during the 2021 Genitourinary Cancers Symposium.

More from Srikala Sridhar

New approaches to curing bladder and kidney cancers: where do we stand?
3:07
New approaches to curing bladder and kidney cancers: where do we stand?
Srikala Sridhar • 30 May 2026
Predictive biomarkers in bladder & kidney cancer: insights into recent progress
0:33
Predictive biomarkers in bladder & kidney cancer: insights into recent progress
Srikala Sridhar • 30 May 2026
JAVELIN Bladder 100: duration of treatment-free interval
3:13
JAVELIN Bladder 100: duration of treatment-free interval
Srikala Sridhar • 8 Jun 2021
Maintenance therapy in urothelial carcinoma
1:02
Maintenance therapy in urothelial carcinoma
Srikala Sridhar • 8 Jun 2021

Related Videos

Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
1:55
Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
Sarah Howlett • 26 Oct 2026
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
2:20
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
Jens Bedke • 26 Oct 2026
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
2:24
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
Jens Bedke • 26 Oct 2026
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
2:58
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
Jens Bedke • 26 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals